UBS Group’s Park Ha Biological Technology Co BYAH Stock Holding History

UBS Group’s Portfolio BYAH Stock Details BYAH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$84	Buy	10 +1	+11%	+$31	﹤0.01%	10143
2025 Q4	$569	Sell	9 -4	-31%	-$485	﹤0.01%	9889
2025 Q3	$2.39K	Buy	13 +9	+225%	+$11.2K	﹤0.01%	9178
2025 Q2	$51.5K	Buy	+4	New	+$26.9K	﹤0.01%	7743
2025 Q1	–	Sell	-8	Closed	-$19.4K	–	10822
2024 Q4	$19.4K	Buy	+8	New	+$16.2K	﹤0.01%	7892

Other funds holding BYAH

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's BYAH Position: Q1 2026 in Review

UBS Group increased its Park Ha Biological Technology Co (BYAH) stake by 11% in Q1 2026, buying an estimated $31 and bringing the position to 10 shares worth $84. The position accounts for ﹤0.01% of the portfolio, ranked #10143.

UBS Group first reported a position in BYAH in Q4 2024 and has held it in 5 quarters since. The position peaked at $51.5K in Q2 2025. 2 funds tracked by Wall St. Rank hold BYAH as of Q1 2026.

UBS Group held 10 shares of Park Ha Biological Technology Co worth $84 as of Q1 2026.
UBS Group bought 1 Park Ha Biological Technology Co share in Q1 2026, an estimated $31.
Park Ha Biological Technology Co made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10143 holding.
UBS Group first reported a position in Park Ha Biological Technology Co in Q4 2024 and has held it in 5 quarters since.
UBS Group's Park Ha Biological Technology Co position peaked at $51.5K in Q2 2025.
2 funds tracked by Wall St. Rank held Park Ha Biological Technology Co as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.